on Biotest AG (ETR:BIO)
Biotest AG Announces New CEO Appointment
Biotest AG has announced a leadership change with the appointment of Dr. Jörg Schüttrumpf as the new Chief Executive Officer (CEO). The Supervisory Board made this decision effective immediately. Dr. Schüttrumpf, who previously served on the Management Board from January 2022 to August 2024, returns after a stint with Grifols S.A., Biotest's main shareholder.
Dr. Schüttrumpf succeeds Peter Janssen, who stepped down by mutual agreement. The Board expressed gratitude to Mr. Janssen for his contributions. This leadership transition marks a significant moment for Biotest, as it continues its focus on biological therapeutics derived from human plasma, catering primarily to clinical immunology, haematology, and intensive care medicine.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biotest AG news